Protecting the World from Pertussis and Other Emerging Diseases

BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure. The company currently distributes a portfolio of vaccines through an established global commercial network and continues to expand its operations across continents.

BioNet Key facts

3

3 licensed
recombinant pertussis vaccines

200

200+ qualified and passionate individuals fueling vaccine innovation

25

25+ years’ experience in vaccines

20

20 clinical trials conducts

10

10+ mRNA candidates

Latest News

Skin patch delivery of a SARS-CoV-2 spike DNA vaccine produces broad neutralising antibody responses

The study demonstrates the effective delivery of a nucleic acid-based COVID-19 vaccine in a preclinical animal study utilizing Vaxxas’ high-density microarray patch (HD-MAP) technology. The DNA vaccine, owned by Technovalia and developed in partnership with BioNet, was conducted in collaboration with The University of Queensland. The research showed that HD-MAPs successfully delivered the vaccine to the skin of animals in a preclinical model, resulting in robust antibody and cell-based immune responses.

BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation

BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in collaboration with LTS Lohmann Therapie-Systeme AG, this recognition underscores BioNet’s contributions to mRNA vaccine technologies and their transformative potential to improve global health.

LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition

Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today their selection as a Concept Stage winner of the #PatchForwardPrize, a $50 million challenge by BARDA to advance microneedle patch-based RNA vaccine technologies. This recognition highlights the groundbreaking potential of their collaboration in mRNA vaccine development and delivery.